Stereotactic body radiation therapy (SBRT) is a widely recognized approach for managing hepatocellular carcinoma (HCC), particularly in its advanced stages, with prognosis highly dependent on tumor burden and baseline liver function.This study aimed to develop a predictive model and nomogram that incorporates these factors to improve survival outcomes in advanced HCC patients treated with SBRT and systemic therapy.We retrospectively reviewed records of 110 patients with advanced HCC treated with SBRT between May 2020 and Apr. 2023.Inclusion criteria included age ≥18 years, cirrhosis, and suitability for SBRT.The median age was 63 years (range 28-84), with viral cirrhosis (40.9%) and NASH (38.2%) as the main etiologies.At presentation, 83.6% of patients had portal vein thrombosis, 32.7% had nodal metastasis, and 50% had distant metastasis.The median tumor diameter was 9 cm, and 73.6% of patients had the multifocal disease.A median SBRT dose of 35 Gy (range 25-45 Gy) in 5 fractions was administered.Significant reductions in tumor markers were noted at three months: AFP levels dropped from a median of 309.75 ng/mL to 62 ng/mL (P = 0.015), and PIVKA II from 2230 mAU/mL to 345 mAU/mL (P = 0.001).Complete and partial responses were seen in 33% and 45% of patients, resp.The median overall survival (OS) was 14 mo (95% CI 11.7-16.2), with OS rates of 90%, 58%, and 34% at 6, 12, and 24 mo.Progression-free survival (PFS) was 9 mo (95% CI 6.4-11.5).Significant predictors of OS included multifocal tumor, portal vein thrombosis, lymph node involvement, serum bilirubin, serum albumin, and log PIVKA-II.The developed MAP-BNP nomogram achieved a C-index of 0.853, outperforming the Child-Turcotte-Pugh (0.62) and ALBI (0.64) scores.Patients were classified into low-risk (<200 points) and high-risk (>200 points) groups, with the low-risk group showing a significantly longer OS (P < 0.001).The MAP-BNP nomogram, integrating tumor burden and liver function, provides a more individualized approach for predicting survival in advanced HCC patients treated with SBRT and systemic therapy, outperforming traditional staging systems.